Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$33.68 - $41.95 $4.99 Million - $6.21 Million
148,130 New
148,130 $6.03 Million
Q1 2023

May 12, 2023

BUY
$32.86 - $55.7 $559,934 - $949,128
17,040 New
17,040 $650,000
Q2 2022

Aug 10, 2022

SELL
$37.35 - $48.3 $4.66 Million - $6.03 Million
-124,869 Closed
0 $0
Q1 2022

May 11, 2022

SELL
$31.97 - $41.06 $2.44 Million - $3.14 Million
-76,417 Reduced 37.96%
124,869 $4.98 Million
Q4 2021

Feb 10, 2022

BUY
$31.82 - $40.75 $5.07 Million - $6.49 Million
159,304 Added 379.46%
201,286 $8.09 Million
Q3 2021

Oct 28, 2021

SELL
$38.47 - $46.42 $270,905 - $326,889
-7,042 Reduced 14.36%
41,982 $1.71 Million
Q2 2021

Aug 10, 2021

BUY
$38.84 - $51.31 $112,208 - $148,234
2,889 Added 6.26%
49,024 $2.23 Million
Q1 2021

Jul 21, 2021

SELL
$39.51 - $51.45 $126,471 - $164,691
-3,201 Reduced 6.49%
46,135 $1.92 Million
Q4 2020

Feb 12, 2021

SELL
$25.81 - $43.62 $3.94 Million - $6.66 Million
-152,765 Reduced 75.59%
49,336 $2.11 Million
Q3 2020

Oct 30, 2020

BUY
$25.74 - $29.63 $2.74 Million - $3.15 Million
106,406 Added 111.19%
202,101 $5.31 Million
Q2 2020

Aug 05, 2020

BUY
$16.25 - $26.81 $175,695 - $289,869
10,812 Added 12.74%
95,695 $2.57 Million
Q1 2020

May 11, 2020

SELL
$13.9 - $21.83 $212,544 - $333,802
-15,291 Reduced 15.26%
84,883 $1.53 Million
Q4 2019

Feb 13, 2020

BUY
$14.93 - $19.53 $1.19 Million - $1.56 Million
79,775 Added 391.07%
100,174 $1.78 Million
Q3 2019

Nov 08, 2019

BUY
$15.2 - $17.69 $310,064 - $360,858
20,399 New
20,399 $316,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.57B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Winton Group LTD Portfolio

Follow Winton Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.